Growth hormone-releasing peptides (GHRPs) 
Introduction
The first peptides of the growth hormone-releasing peptide (GHRP) family were invented rather than isolated in 1977 (1) . Although derivatives of the pentapeptide met-enkephalin, they were devoid of in man after intravenous (i.v.), subcutaneous (s.c), intranasal (i. .) and even oral (p.o.) administration (13-19).
The potent GH-releasing effect seen even after oral administration prompted the research in this field. Now the GHRP family includes more potent analogs to GHRP-6, such as a heptapeptide, GHRP-1 (Ala-His-Dbeta-NaI-Ala-Trp-D-Phe-Lys-NH2). and two hexapeptides, GHRP-2 (D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2) and Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) whose activities have been extensively studied in animals and humans (18, (20) (21) (22) (23) (24) (25) (26) . As (74) . Interestingly, GHRPs have even been reported to induce GH synthesis (73) .
The GH-releasing activity of GHRPs in vitro is lower (86) . These data indicate that cholinergic and adrenergic pathways influence GHRP activity; however, in dogs, while metoxamine, an -I adrenoceptor agonist, does not modify the GH response to GHRP-6, contradictory results about the effect of clonidine, an a-2 adrenocep¬ tor agonist, have been reported (78, 86) .
The GH-releasing activity of GHRPs has also been found to be influenced by steroids (56, 75, 93 (103) (Fig. 2) (Fig. 3) .
Notably, the GH response to GHRPs shows good intraindividual reproducibility (103, 107) , different from that observed with GHRH (108, 109 (132) (Fig. 5) (154) , that in hyperthyroidism is usually reduced (153, 155 (177, 178) .
On the other hand, the possibility that GHRP treatment could usefully enhance the activity of the GH/IGF-I axis in short children with GH (179) .
Aging
It is still unclear whether it is really useful to restore the activity of the GH/IGF-I axis in aging (116, 180, 181) . However, as the pituitary GH releasable pool is preserved in elderly subjects (116) , GH secretagogues are probably the most appropriate approach in restoring GH and IGF-I secretion in order to counteract agerelated changes in body composition, structure function and metabolism, with particular attention to the effects on muscle mass and strength, bone mass and atherogenesis (116, 180. 181 
